Metformin: A Potential Anti-Cancer Agent
Mar 20, 2021
Editor: David L. Joffe, BSPharm, CDE, FACA
Author: Shana Indawala, PharmD Candidate, University of South Florida Health, Taneja College of Pharmacy
Use of metformin was associated with a 16% reduced risk for overall mortality in patients with type 2 diabetes and pancreatic cancer.
In addition to treating patients with type 2 diabetes, recent research has shown that metformin expresses an anti-cancer effect through the rapamycin-signal pathway and the ataxia telangiectasia mutated/liver kinase B1/adenosine 5'-monophosphate-acted protein kinase axis. A relationship between cancer of the pancreas and type 2 diabetes exists, with a significantly higher incidence of cancer and cancer-related mortality in patients with diabetes. Previous epidemiologic research and meta-analysis have showcased the relationship between metformin use and pancreatic cancer risk; however, the relationship is still unclear....
Agreement to pay later is required for access to the full text of this article. You will be charged only after your use reaches $5.00 (US) of site content. The costs of producing a newsletter like Diabetes in Control have been increasing, which is why we are asking our readers to help support our ability to continue to bring you quality information about diabetes through charging a minimal price to read certain articles. Thank you for helping to support Diabetes in Control.